Project Details
Description
PROJECT SUMMARY / ABSTRACT
Approximately 60% of older adults with Alzheimer’s disease or a related dementia (ADRD) have three or more
chronic conditions. Multiple chronic conditions (MCCs) and frailty are also risk factors for ADRD and can affect
the expression of AD pathology with regards to cognitive function, disease stage, and neuropathological
burden. Utilizing biomarkers to diagnosis ADRD may provide a more accurate and cost-effective assessment
of the underlying etiology contributing to the cognitive impairment and may guide treatments and counseling
about individualized care pathways. However, widespread incorporation of these biomarkers into routine
clinical care and population screening programs for older adults with multiple MCCs and cognitive impairment
has not occurred. Blood-based biomarkers are now clinically available to aid in the diagnosis of ADRD and are
more feasible, especially for older adults with MCCs, and less costly and invasive than CSF or PET-based
biomarkers. However, no research has examined these blood biomarkers for the diagnosis and prognosis of
ADRD in primary care, especially among diverse populations. It is unknown how and when these blood
biomarkers should be used, particularly for diagnosis and prognosis among older adults with MCCs and/or
limited life expectancy. Moreover, the effect of MCCs on levels of the biomarkers are not well understood.
Numerous other questions remain, such as: 1) whether the ADRD biomarkers enhance prognosis among older
adults with MCCs and cognitive impairment; 2) for whom it is most beneficial to obtain ADRD biomarkers
including blood, CSF or imaging; 3) how the biomarkers can be implemented in a primary clinical healthcare
delivery model; 4) whether there are subgroup differences (e.g. race/ethnicity, sex, MCCs) that affect the
interpretation of the biomarkers; 5) assessment of cost estimates and risk/benefit ratios for reimbursement; 6)
how best to communicate the results to patients and their caregivers; and 7) the ethical aspects of biomarker
collection and potential for incidental findings due to mixed pathologies, especially among older adults. The
overall goal of this application is to establish a national consortium, the Alzheimer’s Diagnosis in older Adults
with Chronic Conditions (ADACC) Network, consisting of multi-disciplinary investigators that will address these
and other questions, and develop evidence-backed strategies and guidelines for the use and implementation of
biomarkers for ADRD diagnosis in older patients with MCCs and cognitive impairment. The consortium will
have an Executive Committee, Steering Committee, and Data Coordinating Center. It will fund three pilot
projects each year and convene an annual meeting. Working groups will be developed to focus on the
questions listed above and others. Successful completion of the grant aims will advance the diagnosis and
care of older adults with MCCs and cognitive impairment by increasing understanding of how and when to
implement ADRD biomarkers.
Status | Active |
---|---|
Effective start/end date | 9/15/23 → 5/31/24 |
Funding
- National Institute on Aging: $1,884,695.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.